论文部分内容阅读
目的观察自体造血干细胞移植(AHSCT)治疗恶性淋巴瘤的疗效。方法自1998年1月至2003年2月,用AHSCT治疗恶性淋巴瘤15例。外周血干细胞动员均采用CHOP方案+VP16+粒细胞集落刺激因子(G-CSF300μg/d,5~7d)。预处理方案为CBV或改良CHOP方案。结果全部患者均获得缓解,随诊至2003年12月,3年无瘤生存率为86.1%,无移植相关死亡。结论AHSCT联合大剂量化疗对中高度、中晚期恶性淋巴瘤疗效佳,能够提高生存率并优于常规化疗。
Objective To observe the curative effect of autologous hematopoietic stem cell transplantation (AHSCT) on malignant lymphoma. Methods From January 1998 to February 2003, 15 cases of malignant lymphoma were treated with AHSCT. Mobilization of peripheral blood stem cells using CHOP program + VP16 + granulocyte colony-stimulating factor (G-CSF300μg / d, 5 ~ 7d). Pretreatment program for the CBV or improved CHOP program. Results All the patients were relieved. No patient-related deaths were found after 3-year follow-up to December 2003, with a 3-year disease-free survival rate of 86.1%. Conclusion AHSCT combined with high-dose chemotherapy is effective in treating moderate to advanced and advanced malignant lymphoma, which can improve the survival rate and outperform conventional chemotherapy.